Dannenberg Andrew J MD

Biography:Eric Mallack, MD, MBE is an Assistant Professor of Pediatrics and Neurology at Weill Cornell Medical College, Assistant Attending at NewYork-Presbyterian Hospital, and Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center. He is the Director of theLeukodystrophy Centerat Weill Cornell Medicine, and Neurologist in the WCM-MSKCC Metabolic Cell and Gene Therapy Program.Dr. Mallack completed his A.B. in Philosophy and Biomathematics at The University of Scranton. He then simultaneously earned his Medical Doctorate from the Temple University School of Medicine, and his Masters Degree in Bioethics (MBE) from the University of Pennsylvania School of Medicine. Dr. Mallack completed his Pediatrics and Child Neurology Residency training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He completed his post-doctoral research training under the NIH/NINDS Neurological Sciences Academic Development Award (NSADA K12) at the Massachusetts General Hospital Center for Rare Neurological Diseases.Dr. Mallacks clinical interests include the class of diseases known as the leukodystrophies with a special interest in X-Linked Adrenoleukodystrophy, and childhood neurogenetic disorders. His research interests include gene therapy for the leukodystrophies and advanced neuroimaging.About Dr. Mallack's Research Program:Dr. Mallack's translational research program allies with the Newborn Screening Program and Patient/Parent Advocacy Groups to identify presymptomatic patients with X-Linked Adrenoleukodystrophy. He is investigating the ability of multiple advanced neuroimaging techniques, including diffusion tensor imaging, to identify patients appropriate for stem cell transplant or gene therapy prior to symptom onset.Dr. Mallack is an investigator on multiple gene therapy clinical trials:Krabbe Disease: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (GALax-C)Canavan Disease: A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire)Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A): Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)Dr. Mallack is a faculty neurologist in the Center for Neurogenetics which focuses on understanding the genetic mechanisms responsible for abnormal brain development. He is also investigating genotype-phenotype correlations in autism under the Weill Cornell Autism Research Project (WCARP).

Dr. Onyinye Balogun is an Assistant Professor of Radiation Oncology at Weill Cornell Medicine specializing in the treatment of breast and gastrointestinalmalignancies.She is a graduate of Harvard University and Yale University School of Medicine. Dr. Balogun initiatedher residency training at the University of Chicago and completed her final year at New York University.She has conducted and published breast cancer research in novel therapeutics for triple negative breast cancer and brain metastases. She is also engaged in hepatocellular cancer research as well asglobal health activitieswith a focus on improving the delivery of radiation therapy in low and middle income countries.

Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Childrens Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for its leadership in the treatment of patients with lymphoma. Dr. Roths research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth